Lidocaine HCI Injection, by Hospira, Recalled: AttorneyOne Monitors and Keeps Consumers Informed

Share Article

On October 17, the FDA announced that one lot of 1% Lidocaine HCI for Injection, USP, by Hospira, is recalled due to particulate matter. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers.

Lidocaine HCI Injection, by Hospira, Recalled

Lidocaine HCI Injection, by Hospira, Recalled

Anyone with an existing inventory of the recalled lot should stop use and distribution and quarantine the product immediately

AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Lidocaine HCI Injection.

The FDA announced on October 17, that one lot of 1% Lidocaine HCI for Injection, USP, 10 mg per mL, 30 mL Single-dose, Preservative-Free, by Hospira, is recalled due to particulate matter. The reason for the recall is based on a confirmed customer report of particulate in a single unit identified as a human hair, embedded in and attached to a pinched area of the stopper. If the particulate breaks, injected particulate material may cause local inflammation, low-level allergic response to the particulate or microembolic effects and/or phlebitis.

The affected lot NDC 0409-4279-02; Lot 40-316-DK, Expiry 1APRIL2016 was distributed from May 2014 through June 2014.

Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds “we are determined to keep an eye on FDA announcements concerning Lidocaine HCI Injection and inform the public. For that reason", he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out.”

As the FDA recommends “Anyone with an existing inventory of the recalled lot should stop use and distribution and quarantine the product immediately.” And the Agency adds “If you have further distributed the recalled product please notify any accounts or additional locations which may have received the recalled product from you and instruct them if they have redistributed the product to notify their accounts, locations or facilities to the medical facility/retail level.”

AttorneyOne.com has further information on Lidocaine HCI Injection at the website including the latest major drug, food, and medical products law news.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/09/prweb12263560.htm

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sean Burke
Attorney One
+1 877-230-7343
Email >
@Attorney_One
Follow >
Visit website